The meta-analysis between HR+HER2+ and HR-HER2+ BC subtypes only showed significant differences in the CHEK2 germline variant carriers predisposing to HR+HER2+ (pOR: 2.09; 95% CI 1.27–3.44, n=5,471) (Figure 6). This evidence concerns the gene CHEK2 and breast cancer.